President Bioden

1 Like

Executive Order: Biden Unleashes Transhuman, Genetic Modification Firestorm On America

Transhumanists and Technocrats in Big Pharma have cracked the U.S. government wide open to flood the bioeconomy with taxpayer money and labor to push the frontier of genetic modification of all living things, especially humans. This will ultimately spark the biggest public backlash in modern history.

Biden pledges not only funding but an all-of-government transformation to support this anti-human scheme from top to bottom. It also automatically blocks any agency or department from dissent. — Technocracy News & Trends Editor Patrick Wood


“On September 14, 2022, the White House will host a Summit on the National Biotechnology and Biomanufacturing Initiative during which cabinet agencies will announce a wide range of new investments and resources that will allow the United States to harness the full potential of biotechnology and biomanufacturing and advance the President’s Executive Order.

According to a White House fact sheet, the initiative will accelerate biotechnology innovation and grow America’s bioeconomy across multiple sectors in industries such as health, agriculture, and energy. It will “drive advances in biomanufacturing that substitute fragile supply chains from abroad with strong chains at home…

Specifically, the initiative will:

Grow Domestic Biomanufacturing Capacity

Expand Market Opportunities for Biobased Products

Drive Research and Development (R&D) to Solve Our Greatest Challenges

Improve Access to Quality Federal Data

Train a Diverse Skilled Workforce

Streamline Regulations for Products of Biotechnology

Advance Biosafety and Biosecurity to Reduce Risk

Protect the U.S. Biotechnology Ecosystem

Build a Thriving, Secure Global Bioeconomy with Partners and Allies

“And after his administration’s big success passing last month’s CHIPS Act, which will funnel more than $70 billion into the U.S. semiconductor industry to counter China’s dominance in the space, Biden has a new goal in his sights. On Monday, the president signed a new executive order to funnel more cash into U.S. biotechnology research and development.The order will direct a still unspecified amount of money toward U.S. research into biologically derived technologies, which can have applications for everything from developing alternative fuels to mRNA vaccines.”

“The executive order allows the federal government to direct funding for the use of microbes and other biologically derived resources to make new foods, fertilizers and seeds, as well as making mining operations more efficient, administration officials said… Potential applications range from the biodiesel fuels made by Renewable Energy Group to the COVID vaccines made by Pfizer-BioNTech (PFE.N), (22UAy.DE) or the genetically modified seeds made by Corteva Inc (CTVA.N)… Biden will discuss the order in Boston Monday, as he speaks about the “Cancer Moonshot,” an effort to spur research, create new treatments and cut the death rate from that disease.

Biomanufacturing has been used to generate cancer treatments, including those derived from plants or using re-engineered immune cells. Biden also will name Dr. Renee Wegrzyn, a longtime science adviser and who most recently served at the biotech company Ginkgo Bioworks Holdings Inc, (DNA.N) as the first director of the Advanced Research Projects Agency for Health, a U.S. government-run biomedical research group.” Biden's executive order to fund US biomanufacturing industry

“President Biden proposed the creation of the Advanced Research Projects Agency for Health (ARPA-H) to improve the U.S. government’s ability to speed biomedical and health research. Public Law 117-103 was enacted on March 15, 2022, authorizing the establishment of ARPA-H within the U.S. Department of Health and Human Services.” ARPA-H | National Institutes of Health (NIH)

2 Likes

Renee Wegrzyn

Loomis Council Member

Dr. Renee Wegrzyn is Vice President of Business Development at Ginkgo Bioworks and Head
of Innovation at Concentric by Ginkgo where she is currently focused on applying synthetic
biology to outpace infectious disease – including COVID-19 – through biomanufacturing, vaccine,
and diagnostic/biosurveillance innovation. Prior to Ginkgo, she was Program Manager in the
Biological Technologies Office (BTO) of the Defense Advanced Research Projects Agency
(DARPA), where she leveraged the tools of synthetic biology and gene editing to enhance
biosecurity, support the domestic bioeconomy, and thwart biothreats. Her DARPA portfolio
included the Living Foundries: 1000 Molecules, Safe Genes, Preemptive Expression of
Protective Alleles and Response Elements (PREPARE), and Detect it with Gene Editing
Technologies (DIGET) programs. Renee currently serves on the National Academies of
Sciences, Engineering, and Medicine Standing Committee on Biotechnology for National
Security, Scientific Advisory Boards for Revive & Restore, Air Force Research Labs, Nuclear
Threat Initiative, and the Innovative Genomics Institute. Renee holds a PhD and BS in Applied
Biology from the Georgia Institute of Technology, was a Fellow in the Center for Health Security
Emerging Leaders in Biosecurity Initiative (ELBI), and completed her postdoctoral training as an
Alexander von Humboldt Fellow in Heidelberg, Germany.

Dr. Renee Wegrzyn is Vice President of Business Development at Ginkgo Bioworks and Head of Innovation at Concentric by Ginkgo where she is currently focused on applying synthetic biology to outpace infectious disease – including COVID-19 - through biomanufacturing, vaccine, and diagnostic/biosurveillance innovation. Prior to Ginkgo, she was Program Manager in the Biological Technologies Office (BTO) of the Defense Advanced Research Projects Agency (DARPA), where she leveraged the tools of synthetic biology and gene editing to enhance biosecurity, support the domestic bioeconomy, and thwart biothreats. Her DARPA portfolio included the Living Foundries: 1000 Molecules, Safe Genes, Preemptive Expression of Protective Alleles and Response Elements (PREPARE), and Detect it with Gene Editing Technologies (DIGET) programs. Renee currently serves on the National Academies of Sciences, Engineering, and Medicine Standing Committee on Biotechnology for National Security, Scientific Advisory Boards for Revive & Restore, Air Force Research Labs, Nuclear Threat Initiative, and the Innovative Genomics Institute. Renee holds a PhD and BS in Applied Biology from the Georgia Institute of Technology, was a Fellow in the Center for Health Security Emerging Leaders in Biosecurity Initiative (ELBI), and completed her postdoctoral training as an Alexander von Humboldt Fellow in Heidelberg, Germany.

MISSION STATEMENT

Ginkgo Bioworks was founded in 2008 with the mission to make biology easier to engineer.

Engineering biology isn’t easy. It is frustratingly, painfully difficult. It’s programming without a debugger, manufacturing without CAD, and construction without cranes. At Ginkgo we are building a team that can build debuggers, write CAD, and operate cranes. We are looking for the best engineers, scientists, and hackers.

https://www.darpa.mil/program/detect-it-with-gene-editing-technologies

Detect It with Gene Editing Technologies (DIGET)

CDR Jean-Paul Chretien

The DoD requires timely and comprehensive threat detection to support overall readiness, counter the spread of disease, and promote stabilization missions. State of the art diagnostic and biosurveillance systems are unable to keep pace with disease outbreaks and fail to support decision-making at the time and place of need. The “Detect It with Gene Editing Technologies” (DIGET) program aims to leverage advances in gene editing technologies to develop field-forward diagnostic and biosurveillance technologies that enable detection of any threat, anytime, anywhere.

To achieve its goal, DIGET performers will design, develop, prototype, and deploy two novel nucleic acid detection devices: 1) a disposable point-of-need diagnostic for up to 10 pathogens and host biomarkers, and 2) a massively multiplexed detection (MMD) device for 1,000 or more targets. Both devices must be simple to operate, low-cost, and rapidly reconfigurable to provide high-impact, high-quality, and trusted information that enhances decision-making. If successful, the disposable point-of-need device will improve the speed and efficacy of triage and treatment and enhance the standard of care for the military and public health domains in austere environments. The MMD device will enable early threat detection, assess disease severity, and improve situational awareness. The MMD platform will also provide actionable data for biosurveillance efforts such as characterization of known and emergent pathogens in circulation to inform countermeasure deployment.